Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasms 4Small Cell Lung Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Infections 1Colorectal Neoplasms 1Colonic Neoplasms 1COVID-19 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 34Busulfan 32fludarabine phosphate 29Cyclosporine 24Mycophenolic Acid 22Peripheral Blood Stem Cell Transplantation 21Whole-Body Irradiation 19Antilymphocyte Serum 19Tacrolimus 15Methotrexate 15Cytarabine 15fludarabine 14Melphalan 14Cord Blood Stem Cell Transplantation 14Radiotherapy 13Filgrastim 12Methylprednisolone 9Granulocyte Colony-Stimulating Factor 9Etoposide 7Thiotepa 6thymoglobulin 5sargramostim 5Idarubicin 5Cyclosporins 5Clofarabine 5Azacitidine 5merphos 4Gemtuzumab 4Decitabine 4Arsenic Trioxide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anemia, Refractory, with Excess of Blasts × monalizumab × Clear all
NCT06892223 2025-03-24

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

Istituto Clinico Humanitas

Phase 2 Recruiting
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡